Telstar
Telstar has reinforced its pharmaceutical consulting area by driving two new business lines that will offer consulting services for quality systems in GXP environments. Specifically, Telstar has incorporated a new Quality by Design (QbD) deployment service and has expanded its R&D quality systems service for the preclinical (GLP) and clinical (GCP) phases in the development of active ingredients and drugs as well as for pharmacovigilance in the marketing phase.
The expansion of Telstar’s consulting services portfolio took place on 1 February 2013, when the Catalonian company acquired dTC Development Team Consulting's business. dTC Development Team Consulting, which has been in business since 2000, is highly specialised in executing projects that deal with GXP regulatory compliance and with the improvement of manufacturing processes based on QbD concepts. With the integration of dTC’s know-how into its business, Telstar now claims it stands strengthened as the only Spanish company capable of offering a global pharmaceutical consulting service that encompasses the entire drug lifecycle.
The integration of this specialised service enables Telstar to position itself as a leading provider of GLP services for nonclinical development, GCP services for clinical development, QbD services for process development and redesign, PAT/NIR services for process monitoring and control and GMP services for GMP production and operational excellence.
The full range of Telstar’s consultation services has now been consummated by the incorporation of these two business lines, with services related to regulatory affairs and compliance in the life sciences sector.
Telstar, S.A., +34 93 736 16 00, marketing@telstar.eu, www.telstar.eu.